China vs Nepal: The number of people with susceptibility test result for rifampicin
China
79.92
in 2021
Nepal
81.26
in 2021
China rank
95th
Nepal rank
92nd
The number of people with susceptibility test result for rifampicin over time
- China
- Nepal
How they compare
Nepal currently reports 81.26 against 79.92 in China, a difference of 1.34.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was China ahead.
China ranks 95th and Nepal ranks 92nd of 146 countries.
China has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | China | Nepal | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 59.88 | 43.61 | 16.27 | China |
| 2020s | 81.69 | 70.59 | 11.1 | China |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, China or Nepal?
- Nepal, at 81.26 against 79.92 in China as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between China and Nepal?
- 1.34, with Nepal ahead.
- How many years of comparable data are there for China and Nepal?
- 5 years are reported by both, from 2017 to 2021.
- How do China and Nepal rank globally for the number of people with susceptibility test result for rifampicin?
- China ranks 95th and Nepal ranks 92nd of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.